Research Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Principal Investigator 
Vincent C. Ho

Overview

Body Locations and Systems 
Dermatitis
ClinicalTrials.gov# 
NCT03055195
Status 
Recruiting
Study Start/End 
Apr 27, 2017 to Dec 31, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Jaspal Mor, Study Coordinator
Phone 
604-875-5296
Email Address 
jaspal.mor@ubc.ca
Purpose of Study 

 

This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group study that will investigate the efficacy and safety of mepolizumab SC in adolescent and adult subjects with moderate to severe AD. 

 

 

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.